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Summary
Background.  —  The  burden  of  cardiovascular  diseases  is  anticipated  to  rise  in  developing
countries. We  sought  to  describe  the  epidemiology,  management,  and  clinical  outcomes  of
patients hospitalized  with  acute  coronary  syndromes  (ACS)  in  three  countries  in  western  North
Africa.
Methods.  —  Adult  patients  hospitalized  with  a  diagnosis  of  ACS  were  enrolled  in  the  prospective
ACute Coronary  Events  —a multinational  Survey  of  current  management  Strategies  (ACCESS)
registry over  a  13-month  period  (January  2007  to  January  2008).  We  report  on  patients  enrolled
at sites  in  Algeria,  Morocco  and  Tunisia.  A  standardized  form  was  used  to  collect  data  on  patient
characteristics,  treatments  and  outcomes.
Results.  —  A  total  of  1687  patients  with  conﬁrmed  ACS  were  enrolled  (median  age  59  [interquar-
tile range  52,  68]  years;  76%  men),  59%  with  ST-elevation  myocardial  infarction  (STEMI)  and  41%
with non-ST-elevation  ACS  (NSTE-ACS).  During  hospitalization,  most  patients  received  aspirin
Abbreviations: ACCESS, ACute Coronary Events — a multinational Survey of current management Strategies; ACS, acute coronary
yndromes; CI, conﬁdence interval; HR, hazard ratio; MI, myocardial infarction; NSTE-ACS, non-ST-elevation acute coronary syndromes;
CI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.
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(96%)  and  a  statin  (90%),  83%  received  a  beta-blocker  and  74%  an  angiotensin-converting  enzyme
inhibitor.  Among  eligible  STEMI  patients,  42%  (419/989)  did  not  receive  ﬁbrinolysis  or  undergo
percutaneous  coronary  intervention.  All-cause  death  at  12  months  was  8.1%  and  did  not  differ
signiﬁcantly  between  patients  with  STEMI  or  NSTE-ACS  (8.3%  vs  7.7%,  respectively;  Log-rank
test P  =  0.82).  Clinical  factors  associated  with  higher  risk  of  death  at  12  months  included  car-
diac arrest,  cardiogenic  shock,  bleeding  episodes  and  diabetes,  while  percutaneous  coronary
intervention  and  male  sex  were  associated  with  lower  risk.
Conclusions.  —  In  this  observational  study  of  ACS  patients  from  three  Maghreb  countries,  the
use of  evidence-based  pharmacological  therapies  for  ACS  was  quite  high;  however,  42%  of  the
patients with  STEMI  were  not  given  any  form  of  reperfusion  therapy.
© 2012  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  — La  fréquence  des  maladies  cardiovasculaires  est  devenue  inquiétante  dans  les  pays
en développement.  Par  ce  travail,  nous  avons  cherché  à  décrire  l’épidémiologie,  les  modalités
de prise  en  charge  et  le  devenir  clinique  des  patients  hospitalisés  pour  un  syndrome  coronarien
aigu (SCA)  dans  le  Maghreb.
Méthodes.  —  Des  patients  adultes  hospitalisés  pour  SCA  ont  été  enrôlés  pour  un  suivi  d’un  an
dans cette  étude  prospective  multicentrique  sur  les  stratégies  actuelles  de  prise  en  charge  des
SCA (ACCESS).  La  période  d’inclusion  a  duré  environ  13  mois  (début  janvier  2007  à  ﬁn  janvier
2008). Nous  rapportons  les  données  des  patients  inclus  en  Algérie,  au  Maroc  et  en  Tunisie.  Un
formulaire  identique  dans  les  trois  pays  (registre  ACCESS)  a  été  utilisé  pour  recueillir  des  don-
nées cliniques  et  paracliniques  des  patients,  les  thérapeutiques  instaurées  et  les  résultats  du
suivi.
Résultats. —  Un  total  de  1687  patients,  présentant  un  SCA  conﬁrmé,  ont  été  inclus.  L’âge  moyen
est 59  ans  avec  des  extrêmes  de  52  à  68  ans  ;  76  %  des  patients  étaient  de  sexe  masculin,  59  %
avaient un  SCA  ST+  (STEMI)  et  41  %  un  SCA  ST—.  Pendant  l’hospitalisation,  la  plupart  des  patients
recevaient  de  l’aspirine  (96  %)  et  une  statine  (90  %),  83  %  ont  rec¸u  un  bêta-bloquant  et  74  %  un
inhibiteur de  l’enzyme  de  conversion.  Parmi  les  patients  atteints  de  STEMI,  42  %  (419/989)
n’ont pas  rec¸u  un  traitement  thrombolytique  ou  une  angioplastie  coronarienne  percutanée.
La mortalité  toute  cause  confondue  à  12  mois  était  de  8,1  %  et  ne  diffère  pas  signiﬁcativement
entre les  patients  atteints  de  STEMI  ou  non  STEMI  (8,3  %  vs  7,7  %,  p  =  0,82).  Les  facteurs  cliniques
associés  à  un  risque  plus  élevé  de  décès  à  12  mois  comprennent  un  arrêt  cardiaque,  un  choc
cardiogénique,  des  épisodes  de  saignement  et  un  diabète,  tandis  que  l’angioplastie  coronaire
percutanée  et  le  sexe  masculin  ont  été  associés  à  un  risque  de  mortalité  plus  faible.
Conclusions.  — Dans  cette  étude  observationnelle  de  patients  présentant  un  SCA  dans  trois
pays du  Maghreb,  l’utilisation  des  thérapies  pharmacologiques  fondées  sur  des  preuves  était
assez élevée,  mais  42  %  des  patients  atteints  de  STEMI  n’ont  rec¸u  aucune  forme  de  thérapie  de
reperfusion.
© 2012  Elsevier  Masson  SAS.  Tous  droits  réservés.
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In  recent  years,  large  multinational  registries  have  pro-
vided  novel  insights  into  the  characteristics,  management
and  outcomes  of  the  spectrum  of  patients  with  acute  coro-
nary  syndromes  (ACS)  treated  in  everyday  clinical  practice.
Several  of  these  studies  have  reported  decreased  mortality
rates  associated  with  improved  adherence  to  evidence-
based  ACS  treatments  [1—3]. While  observational  studies
offer  new  and  valuable  information  that  cannot  be  pro-
vided  in  the  narrower  conﬁnes  of  clinical  trials,  so  far  they
have  been  limited  largely  to  European  and  North  Ameri-
can  populations.  Only  limited  data  are  available  for  ACS
patients  outside  of  these  regions  [4—9]. Given  the  antici-
pated  increase  in  burden  of  cardiovascular  morbidity  and
mortality  predicted  for  developing  countries,  it  is  now
E
p
(mperative  to  investigate  how  patients  in  such  countries
re  being  managed  and  how  their  outcomes  compare  with
atients  in  developed  countries.  These  studies  have  the
otential  to  raise  awareness  of  the  disease  and  identify
pportunities  for  improved  treatment  and  patient  out-
omes.
The  aim  of  the  multinational  observational  ACute  Coro-
ary  Events  —  a  multinational  Survey  of  current  management
trategies  (ACCESS)  registry  was  to  describe  the  charac-
eristics,  management  and  1-year  outcomes  of  patients
ospitalized  with  non-ST-segment  elevation  ACS  (NSTE-
CS)  or  ST-segment  elevation  myocardial  infarction  (STEMI)
n  countries  in  Africa,  Latin  America,  and  the  Middle
ast  [10]. In  this  report,  we  describe  the  data  for
atients  enrolled  in  three  countries  in  western  North  Africa
‘‘Maghreb’’).
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ethods
he  rationale  and  methods  for  the  ACCESS  study  have  been
escribed  in  detail  elsewhere  [10]. ACCESS  is  a  prospective,
ultinational,  observational  registry  of  patients  hospital-
zed  for  an  ACS.  Patients  were  enrolled  between  January
007  and  January  2008  at  134  sites  in  19  countries  in  western
orth  Africa  (‘‘Maghreb’’:  Algeria,  Morocco,  Tunisia),  South
frica,  Latin  America  (Argentina,  Brazil,  Colombia,  Domini-
an  Republic,  Ecuador,  Guatemala,  Mexico,  Venezuela)  and
he  Middle  East  (Egypt,  Iran,  Jordan,  Kuwait,  Lebanon,  Saudi
rabia,  United  Arab  Emirates).
The  registry  was  conducted  in  accordance  with  the
uidelines  for  Good  Epidemiological  Practice  and  under
he  leadership  of  a  scientiﬁc  advisory  board.  Participat-
ng  countries  were  responsible  for  ensuring  that  the  study
as  performed  in  accordance  with  local  regulations.  Local
nstitutional  review  boards  or  independent  ethics  commit-
ees  approved  the  study  and  all  patients  provided  signed
nformed  consent.
tudy setting and site selection
 questionnaire  was  sent  to  all  potential  sites  to  collect
ata  on  the  type  of  institution  (public,  private,  teaching),
ts  location,  the  number  of  ACS  patients  treated  and  the  ser-
ices  offered.  The  afﬁliate  in  each  country  then  provided  a
ist  of  centres  that  represented  their  country  as  completely
s  possible.  The  ﬁnal  list  of  investigators  (including  cardio-
ogists  and  internists)  was  then  randomly  generated  by  the
rial  manager.  Physicians  who  declined  to  participate  were
eplaced  by  the  following  physician  in  the  list.  The  aim  was
o  enroll  approximately  25  patients  per  site,  with  at  least
0  sites  per  country.
tudy population
ligible  patients  were  those  aged  21  years  or  above  admitted
o  hospital  for  an  ACS.  Patients  with  symptoms  precipitated
y  a  comorbidity  such  as  anaemia,  heart  failure  or  non-
ardiac  trauma,  and  patients  participating  in  concomitant
linical  trials,  were  excluded.  Patients  were  recruited  con-
ecutively  to  avoid  selection  bias.
Patients  had  to  present  ischaemic  symptoms  of  ACS
ithin  24  hours  of  hospital  presentation  and  have  one  or
ore  of  the  following  characteristics:
electrocardiographic  changes  (transient  ST-segment  ele-
vation  ≥  1  mm,  ST-segment  depression  ≥  1  mm,  new  T-
wave  inversion  ≥  1  mm,  pseudonormalization  of  previ-
ously  inverted  T-waves,  new  Q  waves  [one-third  the  height
of  the  R  wave  or  >  0.04  seconds],  new  R  wave  >  S  wave  in
lead  V1,  or  new  left  bundle  branch  block);
documentation  of  coronary  artery  disease  (history  of
myocardial  infarction  [MI],  angina,  congestive  heart  fail-
ure  believed  to  be  due  to  ischaemia  or  resuscitated
sudden  cardiac  death,  history  of  or  new  positive  stress
test  with  imaging,  previous  or  new  cardiac  catheterization
documenting  coronary  artery  disease,  prior  or  new  percu-
taneous  coronary  intervention  or  coronary  artery  bypass
graft  [CABG]  surgery);
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an increase  in  a  cardiac  biochemical  marker  of  myocardial
necrosis  (troponin  or  CK-MB).
valuations and clinical outcomes
 standardized  case  report  form  (see  Appendix  B  in  Mon-
alescot  et  al.  [10]) was  used  to  record  data  prospectively
t  hospital  admission,  at  discharge,  and  at  6  ±  1  and  12  ±  1
onth  follow-up.  Data  were  collected  during  follow-up
isits  or  by  telephone  calls  to  the  patient  or  a third  party
e.g.  relative/friend,  family  physician).  The  data  collected
t  baseline,  included  demographics,  medical  history,  risk
actors,  physical  examination,  cardiac  biomarkers,  ankle-
rachial  index,  Killip  class,  chronic  medical  treatments  and
ealth  insurance  status.  Data  collected  at  discharge  from
ospital  included  discharge  status  and  diagnosis,  hospi-
al  management,  cardiac  biomarkers  and  hospital  events.
ollow-up  data  included  clinical  outcomes  after  discharge
ncluding  those  leading  to  rehospitalization,  and  treatments
ince  discharge  or  previous  follow-up.
Data  quality  control  was  performed  by  trained  personnel
t  ≥  10%  of  sites  chosen  at  random  in  each  country.  All  case
eport  forms  were  monitored  for  source  documentation  and
ccuracy.  Data-request  forms  were  generated  automatically
n  response  to  queries  and  resolved  by  the  site  investigators.
The  primary  endpoint  was  all-cause  death  at  1  year.  Sec-
ndary  endpoints  (at  1  year)  were  cardiovascular  death;
on-fatal  stroke;  non-fatal  MI;  bleeding;  and  the  combined
ndpoint  of  cardiovascular  death,  stroke  or  MI  [11]. All-
ause  death  at  30  days  was  also  recorded.  Full  deﬁnitions
or  selected  evaluations  and  outcomes  are  given  in  the
ppendix.
tatistical analysis
he  study  population  comprised  patients  enrolled  in  the
rench-speaking  Maghreb  countries  (Algeria,  Morocco  and
unisia)  participating  in  ACCESS.
Statistical  analyses  were  performed  at  the  5%  signiﬁcance
evel,  using  two-sided  tests  or  two-sided  conﬁdence  inter-
als  (CIs).  Continuous  data  are  given  as  mean  ±  standard
eviation  (SD)  or  median  (interquartile  range).  A  P
alue  ≤  0.05  was  considered  to  be  statistically  signiﬁcant.
ategorical  data  are  summarized  using  counts  and  percent-
ges.  Data  were  analysed  with  the  SAS  package,  release
.1.3  (SAS  Institute,  Cary,  NC).
unding
he  ACCESS  registry  was  sponsored  by  Sanoﬁ-Aventis,  Paris,
rance.
esults total  of  1720  patients  were  recruited  by  144  physicians
t  21  sites  in  Algeria,  28  sites  in  Morocco  and  15  sites  in
unisia  between  January  2007  and  January  2008.  Most  of  the
articipating  physicians  were  non-interventional  (57.6%)  or
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Figure 1. Study ﬂowchart: Maghreb population.
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Iinterventional  (34.7%)  cardiologists,  while  4.9%  were  hospi-
tal  physicians  and  2.8%  were  internists.
Study population
The  patient  ﬂow  chart  is  shown  in  Fig.  1.  Of  the  1720
patients  enrolled,  33  with  ‘‘other  cardiac’’,  ‘‘other’’  or
missing  diagnoses  were  excluded.  A  total  of  1687  patients
had  a  conﬁrmed  ACS  diagnosis:  59%  with  STEMI  and  41%
with  non-ST-elevation  ACS  (NSTE-ACS).  Over  the  course  of
the  study,  139  patients  died,  95  were  lost  to  follow-up,  two
withdrew  consent,  and  22  were  excluded  for  another  rea-
son.  Data  were  available  for  1687  patients,  1429  of  who
had  1-year  follow-up  data  (85%  of  the  Maghreb  popula-
tion).
The  baseline  characteristics  of  the  population  are  given
in  Table  1.  The  overall  population  comprised  79%  Caucasians
and  20%  Arabs.  Patients  with  NSTE-ACS  were  slightly  older
than  those  with  STEMI  and  had  a  more  frequent  medical  his-
tory  of  angina,  myocardial  infarction,  and  congestive  heart
c
(
a
7ailure.  Patients  with  STEMI  were  more  commonly  men,
nd  were  more  likely  to  be  tobacco  smokers  and  to  mis-
se  alcohol.  The  mean  (SD)  GRACE  risk  score  [12]  was  119.6
36.9).
The  median  (Q1,  Q3)  delay  from  onset  of  symptoms  to
ospital  admission  was  7.0  (3.0,  23.7)  hours,  and  was  shorter
mong  STEMI  patients  than  NSTE-ACS  patients  (6.0  [2.8,
8.2]  vs  10.4  [3.0,  33.6]  hours).
Almost  one-third  (n  =  511,  31%)  of  patients  had  no  medical
nsurance;  the  remaining  patients  had  government  insurance
n  =  1042,  62%),  private  insurance  (n  =  107,  6.4%)  or  both
n  =  12,  0.7%).
anagement in hospital and at discharge
nformation  on  in-hospital  management  according  to  dis-
harge  diagnosis  is  given  in  Table  2.  Most  ACS  patients
n  =  1625,  96%)  received  aspirin,  a  statin  (n  =  1510,  90%)
nd  an  angiotensin-converting  enzyme  inhibitor  (n  =  1249,
4%)  or  angiotensin  II  receptor  antagonist  (n  =  111,  6.6%).
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Table  1  Patient  baseline  characteristics,  overall  and  according  to  discharge  diagnosis,  in  Maghreb  countries.
All  ACS
(n =  1687)
NSTE-ACS
(n =  698)
STEMI
(n =  989)
Men  76  68  82
Age,  years  59  [52,68]  60  [53,68]  58  [52,67]
Ethnicity
Caucasian 79  75  82
Middle  East  (Arab) 20 24 18
Other 0.8 1.1 0.6
Presenting  characteristics
Pulse,  beats/min 79  [68,90] 76  [66,89] 80  [70,92]
Systolic  BP,  mmHg  124  [110,141]  130  [115,147]  119  [105,137]
Diastolic  BP,  mmHg  73  [65,83]  77  [67,84]  71  [64,81]
Ankle-brachial  index  <  0.9  13  14  11
LVEF,  %  55  [45,62]  60  [52,66]  50  [41,58]
Killip  class  II—IV  17 13 20
Medical  history
Angina  40  51  32
Family  history  of  CVD  14  15  14
Myocardial  infarction  12  14  11
Congestive  heart  failure  2.8  3.9  2.1
Peripheral  artery  disease  3.4  3.6  3.3
TIA/stroke  3.0  3.6  2.6
Bleeding  0.4  0.3  0.5
PCI 4.5  6.4  3.1
CABG  1.2  2.6  0.3
Risk  factors
Hypertension  45  55  37
Dyslipidemia  22  29  17
Diabetes  37  40  34
Overweight  (BMI  25  —  <  30  kg/m2)  42  40  43
Obese  (BMI  ≥  30  kg/m2)  19  22  17
Abdominal  obesitya 67  71  64
Current  smokerb 47  40  51
Alcohol  misusec 4.1  3.3  4.7
Data are % or median [Q1, Q3]. NSTE-ACS: non-ST-segment elevation acute coronary syndrome; STEMI: ST-segment elevation myocardial
infarction; BP: blood pressure; LVEF: left ventricular ejection fraction; CVD: cardiovascular disease; PCI: percutaneous coronary
intervention; CABG: coronary artery bypass graft; TIA: transient ischemic attack; BMI: body mass index.
a Waist circumference: Caucasian, Black, Middle East (Arab): ≥ 94 cm for men; ≥ 80 cm for women. Native Latin American and Asian:
≥ 90 cm for men; ≥ 80 cm for women (according to International Diabetes Federation).
b ≥ 5 cigarettes for ≥ 6 months.
c > 14 units/week for men; > 7 units/week for women.
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t thienopyridine  was  used  in  77%  (n  =  1293)  of  patients,
eta-blockers  in  83%  (n  =  1401)  and  intravenous  glycoprotein
Ib/IIIa  inhibitor  in  9.7%  (n  =  164).  Of  the  989  patients  with
TEMI,  30%  (n  =  298)  received  ﬁbrinolytic  therapy,  most  fre-
uently  with  streptokinase  (92%),  followed  by  tenecteplase
6.4%)  and  alteplase  (1.7%).
During  the  initial  hospitalization,  coronary  angiography
as  done  in  less  than  half  of  the  patients  (n  =  757,  45%).
ercutaneous  coronary  intervention  (PCI)  was  performed  in
2%  of  patients  with  NSTE-ACS  and  in  27%  with  STEMI,  97%
f  whom  received  a  stent  (Table  2).  Forty-two  per  cent
n  =  419)  of  eligible  STEMI  patients  received  no  form  of  acute
C
B
oeperfusion  therapy  (i.e.  PCI  or  ﬁbrinolytic  therapy  within
4  hours  of  admission  to  hospital).
Selected  treatments  at  discharge  from  hospital  are  shown
n  Table  3.  A  large  proportion  of  patients  were  treated
ith  aspirin  (94%),  statins  (84%),  beta-blockers  (82%)  and
hienopyridines  (73%).ountry comparisons
oth  in-hospital  and  at  discharge,  the  highest  rates
f  use  of  angiotensin-converting  enzyme/angiotensin  II
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Table  2  Selected  in-hospital  management:  medications  and  interventions.
All  ACS
(n =  1687)
NSTE-ACS
(n =  698)
STEMI
(n =  989)
Medications
Aspirin  96  96  97
ACE  inhibitor 74  65  80
Angiotensin  II  receptor  blocker 6.6  8.6  5.2
Beta-blocker 83 83 83
Calcium  channel  blockers 20 26 13
Glycoprotein  IIb/IIIa  inhibitor  (intravenous)  9.7  9.0  10
Thienopyridine  77  76  77
Other  antiplatelet  0.4  0.1  0.5
Fibrinolytic  therapy  (no  contraindications)  19  2.0  30
Unfractionated  heparin  38  24  48
Enoxaparin  (subcutaneous)  67  76  61
Other  LMWH  1.2  1.1  1.3
Bivalirudin  or  fondaparinux  0.1  0.1  0
Nitrate/other  anti-angina  drug  71  77  68
Statin  90  90  89
Other  lipid-lowering  drug  1.1  1.0  1.1
Interventions  and  procedures
Coronary  angiography 45  46  44
CABG  surgery  1.5  1.7  1.3
PCI  (any) 25 22  27
With  stenta 97 97 97
Drug-eluting  stenta 24 28 22
PCI  within  24  h  of  admission 48 37  55
Data are %. NSTE-ACS: non-ST-segment elevation acute coronary syndrome; STEMI: ST-segment elevation myocardial infarction; LHWH:
low-molecular-weight heparin; ACE: angiotensin-converting enzyme; CABG: coronary artery bypass graft; PCI: percutaneous coronary
intervention.
a Among patients who had PCI during initial hospitalizationreceptor  antagonist,  beta-blockers  and  statins  were  in  Alge-
ria;  aspirin  was  less  frequently  used  in  Tunisia  (Table  4).
Fibrinolytic  therapy  for  treatment  of  STEMI  was  infrequent
in  Morocco  (8.6%,  39/452).  Early  PCI  for  patients  with
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Table  3  Selected  treatments  at  discharge  according  to  discha
Variable  All  ACS
(n =  1687)
Aspirin 94  
ACE  inhibitors  73  
Angiotensin  II  receptor  blockers  6.6  
Beta-blockers  82  
Calcium  channel  blockers  17  
Thienopyridine 73  
Other  antiplatelet 0.1  
Statin 94
Other  lipid-lowering  drug 0.8  
Nitrates/other  anti-anginal  drugs  49  
Data are %. NSTE-ACS: non-ST-segment elevation acute coronary synd
angiotensin-converting enzyme.TEMI  was  2.5%  in  Algeria  and  22%  in  both  Tunisia  and
orocco.  The  rate  of  no  reperfusion  was  highest  in  Tunisia
60%),  intermediate  in  Algeria  (50%)  and  lowest  in  Morocco
30%).
rge  diagnosis.
NSTE-ACS
(n  =  698)
STEMI
(n  =  989)
94  94
64  80
8.7  5.0
81  82
25  11
71  74
0  0.1
93 95
0.6  0.9
54  46
rome; STEMI: ST-segment elevation myocardial infarction; ACE:
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Table  4  Selected  treatments  by  country.
Algeria  Tunisia  Morocco
All  ACS
(n =  598)
NSTE-ACS
(n =  234)
STEMI
(n  =  364)
All ACS
(n =  335)
NSTE-ACS
(n =  162)
STEMI
(n  =  173)
All ACS
(n  =  754)
NSTE-ACS
(n  =  302)
STEMI
(n =  452)
During  hospitalization
Aspirin  99  99  100  94  92  95  95  95  95
ACE/ARB  97  91  100  76  69  83  70  63  74
Beta-blocker  91  91  91  84  84  84  76  77  76
Statin  93  97  91  94  92  95  85  83  86
Angiography  39  49  33  70  62  78  38  36  39
CABG  0.8  0.9  0.8  2.7  3.7  1.7  1.5  1.3  1.5
Reperfusion  strategy
PCI  during  hospitalization  14  15  12  42  31  52  27  23  30
PCI  within  24  h  of
hospitalization,  %  (of  overall
STEMI  population)
— —  2.5  (n  =  9)  —  —  22  (n  =  38)  —  —  22  (n  =  98)
Fibrinolytic  therapy  —  —  48  —  —  49  —  —  8.6
No  reperfusion  —  —  50  —  —  60  —  —  30
At  discharge
Aspirin  95  95  95  90  90  90  94  95  94
ACE/ARB  93  87  97  74  67  81  72  64  77
Beta-blocker  90  88  92  80  79  81  76  77  75
Statin  98  99  98  93  90  96  91  90  92
Data are %. ACE: angiotensin-converting enzyme; ARB: angiotensin II receptor blocker; CABG: coronary artery bypass graft; NSTE-ACS: non-ST-segment elevation acute coronary syndrome;
PCI: percutaneous coronary intervention; STEMI: ST-segment elevation myocardial infarction.
ACS  management  in  Maghreb  countries  
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Clinical outcomes
The  rate  of  30-day  all-cause  death  was  4.1%  rising  to  8.1%
by  12  months,  and  did  not  differ  between  ACS  subgroups
(Table  5;  P  =  not  signiﬁcant).  Kaplan—Meier  survival  curves
show  an  early  risk  of  death  up  to  approximately  50  days,
which  was  similar  in  both  ACS  subgroups  (Fig.  2;  P  =  not  sig-
niﬁcant).
The  12-month  event  rates  for  the  other  outcomes  are
shown  in  Table  5.  The  rate  of  cardiovascular  death  was  6.2%
overall,  and  was  slightly  but  not  statistically  signiﬁcantly
lower  among  patients  with  NSTE-ACS  versus  STEMI.  Non-fatal
stroke  occurred  in  2.3%  of  ACS  patients,  non-fatal  myocar-
dial  infarction  in  4.4%  and  bleeding  in  4.1%.  The  composite
of  non-fatal  outcomes  plus  cardiovascular  death  was  12%,
and  was  consistent  across  ACS  subgroups.
Among  the  136  patients  who  died  within  12  months
of  presentation  for  an  ACS,  the  most  common  reasons
were  ‘‘other’’  cardiovascular  death  (including  sudden  death
of  unknown  cause;  38%)  and  myocardial  infarction  (32%).
Deaths  were  due  to  strokes  in  5.9%  of  patients  and  for  non-
cardiovascular  reasons  in  5.1%.  The  remaining  deaths  (18%)
were  of  unknown  cause.
When  analysed  by  country,  the  rates  of  all-cause  death
(both  overall  and  in  the  NSTE-ACS  subgroup)  were  lowest
in  Tunisia,  intermediate  in  Morocco  and  highest  in  Algeria
(Fig.  3).
According  to  a  Cox  proportional  hazards  model,  factors
associated  with  a  higher  risk  of  death  at  12  months  were
cardiac  arrest  during  initial  hospitalization  (hazard  ratio
[HR]  13.41,  P  <  0.0001),  cardiogenic  shock  during  hospital-
ization  (HR  4.66,  P  <  0.0001),  bleeding  during  hospitalization
(HR  2.78,  P  =  0.0055),  age  (HR  1.67,  P  =  0.0083)  and  history
of  diabetes  (HR  1.44,  P  =  0.055).  Factors  associated  with  a
lower  risk  were  male  sex  (HR  0.63,  P  =  0.014)  and  PCI  (HR
0.25,  P  <  0.001).Discussion
The  present  study  reports  on  the  contemporary  management
and  outcomes  for  1687  patients  hospitalized  for  an  ACS  in
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hree  countries  in  western  North  Africa  —  Algeria,  Morocco
nd  Tunisia.  Fifty-nine  per  cent  of  the  patients  were  given  a
ischarge  diagnosis  of  STEMI  and  the  remaining  41%  a  diagno-
is  of  NSTE-ACS.  Patients  with  STEMI  were  slightly  younger
han  those  with  NSTE-ACS,  were  more  likely  to  be  male,
ave  a  less  frequent  history  of  cardiac  disease,  fewer  risk
actors  and  a lower  systolic  arterial  blood  pressure;  they
id,  however,  have  a  higher  heart  rate  and  were  more  often
obacco  smokers  and  heavy  drinkers.  The  all-cause  mortal-
ty  rate  rose  from  4.1%  at  30  days  to  8.1%  at  1  year  and  did
ot  differ  between  ACS  subgroups.
aghreb population vs other observational
ata
he  patients  enrolled  in  the  Maghreb  countries  differed
rom  those  in  the  overall  ACCESS  population,  which  involved
1,731  patients  with  an  ACS  [10], and  in  which  54%  were
iagnosed  with  NSTE-ACS  versus  only  41%  in  Maghreb.  The
roportion  of  NSTE-ACS  patients  in  the  Maghreb  population  is
uch  lower  than  that  reported  in  predominantly  ‘‘Western’’
CS  populations  such  as  the  Global  Registry  of  Acute  Coro-
ary  Events  (GRACE)  (66%)  [13]  and  the  second  Euro  Heart
urvey  (EHS-ACS-II)  (48%)  [3],  but  also  in  Arab  populations
s  shown  in  the  Gulf  RACE  study  (61%)  [13]. In  the  Indian
REATE  registry,  however,  which  involved  over  20,000  ACS
atients  (mean  age  58  ±  12  years),  39%  were  diagnosed  with
STE-ACS.
The  Maghreb  ACCESS  ACS  population  appears  intermedi-
te  between  the  GRACE  registry  and  the  Gulf  RACE  registry
n  terms  of  mean  age  at  presentation  (60  years  vs  66  years
n  GRACE  and  56  years  in  Gulf  RACE),  proportion  of  men
76%  vs  69%  and  76%)  and  rate  of  hypertension  (45%  vs  66%
nd  50%).  In  the  STEMI  population,  however,  the  propor-
ion  of  patients  with  diabetes  mellitus  was  highest  in  the
aghreb  patients  (34%  vs  22%  in  GRACE  and  32%  in  Gulf
ACE).
When  compared  with  the  overall  ACCESS  data  [10],
atients  in  Maghreb  had  lower  rates  of  cardiac  risk  factors,
edical  histories  of  angina,  cardiac  disease  and  bleeding,
nd  family  histories  of  cardiovascular  disease.  In  contrast,  a
reater  percentage  of  Maghreb  patients  were  tobacco  smok-
rs.  The  rate  of  smoking  was  also  higher  than  reported  in
ther  observational  studies  (40%  vs  28%  in  GRACE  and  37%
n  Gulf  RACE  [13]), was  the  same  as  in  the  CREATE  registry
40%)  [7],  but  was  lower  than  in  a  Tunisian  study  of  patients
ith  myocardial  infarction  (63%)  [8].
These  differences  suggest  that  patients  in  the  Maghreb
egion,  similar  to  those  in  the  Indian  CREATE  registry,  tend
o  present  at  a  younger  age.  They  also  suggest  insufﬁcient
ublic  awareness  of  the  negative  impact  of  smoking  on  car-
iovascular  disease,  and  provide  an  incentive  to  encourage
he  adoption  of  anti-smoking  campaigns  and  smoking  bans
n  public  areas.
ariations in managementhen  compared  with  the  overall  ACCESS  population  [10],
he  use  of  beta-blockers  (83%  vs  78%  overall)  and  aspirin  (96%
s  93%  overall)  was  slightly  higher  in  the  Maghreb  countries,
574  A.  Moustaghﬁr  et  al.
Table  5  Clinical  events:  Maghreb  population  and  overall  ACCESS  population.
Event  Maghreb  countries  Overall  ACCESS  populationa
All  ACS
(n =  1687)
NSTE-ACS
(n  =  698)
STEMI
(n  =  989)
All  ACS
(n =  11,731)
NSTE-ACS
(n  =  6320)
STEMI
(n  =  5411)
All-cause  mortality  at  30  days  4.1  4.0  4.2  3.6  2.4  5.0
Events  at  12  months
All-cause  mortality  8.1  7.7  8.3b 7.3  6.3  8.4
Cardiovascular  death  6.2  5.4  6.7b 5.6  4.7  6.8
Non-fatal  stroke  2.3  2.1  2.3b 2.0  2.1  1.9
Non-fatal  MI  4.4  4.9  4.1b 3.0  3.1  2.8
Bleeding 4.1  3.7  4.3b 4.8  4.4  5.2
CV  death,  non-fatal  stroke,  MI  12  12  12  10  9.3  11
Data are %. MI: myocardial infarction; NSTE-ACS: non-ST-segment elevation acute coronary syndrome; STEMI: ST-segment elevation
myocardial infarction.
a Adapted from Montalescot et al. [10].
b P = not signiﬁcant for NSTE-ACS vs STEMI.
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Fnd  was  in  line  with  the  results  reported  for  other  studies
≥  95%)  [1,3]. Similarly,  Maghreb  physicians  showed  a  pref-
rence  to  use  the  low-molecular-weight  heparin  enoxaparin
76%  in  Maghreb  vs  57%  in  overall  ACCESS)  over  unfraction-
ted  heparin  (24%  vs  37%)  in  patients  with  NSTE-ACS.  In  line
ith  the  overall  data,  other,  newer  anticoagulants  such  as
ondaparinux  or  bivalirudin  were  almost  never  used.
Coronary  angiography  (45%  in  Maghreb  vs  58%  over-
ll  ACCESS)  and  PCI  (25%  vs  35%  overall)  were  performed
uch  less  frequently  in  Maghreb  when  compared  with  the
verall  ACCESS  population  [10]  and  other  registry  studies
uch  as  GRACE  and  EHS-ACS-II  [1,3], but  were  used  sub-
tantially  more  frequently  than  in  the  Gulf  RACE  study
b
a
igure 2. Survival curves up to 1 year for patients with STEMI and NST21%  for  coronary  angiography  and  7%  for  PCI)  [6]  or  the
ndian  CREATE  registry  (23%  and  7.5%,  respectively)  [7].
mong  patients  with  STEMI  or  left  bundle  branch  block,  the
ulf  RACE  data  showed  a  very  high  rate  of  use  of  throm-
olysis  (93%;  65%  overall  rate  of  reperfusion),  compared
ith  only  30%  (58%  overall  rate  of  reperfusion)  in  STEMI
atients  in  Maghreb.  Similarly,  the  CREATE  registry  reported
 higher  rate  of  reperfusion  with  ﬁbrinolytic  therapy  for
atients  with  STEMI  (59%)  but  a  very  low  rate  of  in-hospital
CI  (8.0%)  [7].At  discharge  from  hospital,  the  use  of  evidence-
ased  ACS  medications  including  aspirin,  ACE  inhibitors/
ngiotensin-converting  enzyme  receptor  blockers,
E-ACS: Maghreb population. Log-rank test P = 0.83.
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AACS  management  in  Maghreb  countries  
beta-blockers  and  statins  was  reassuringly  high,  and
was  greater  than  in  the  overall  ACCESS  registry  [10].
Clinical outcomes
The  rate  of  all-cause  30-day  mortality  in  the  Maghreb  ACCESS
population  was  higher  than  that  in  the  overall  ACCESS  pop-
ulation  (4.1%  vs  3.6%)  [10], driven  by  a  higher  rate  of  death
among  patients  with  NSTE-ACS  (4.0%  vs  2.4%)  and  despite
the  lower  rate  among  STEMI  patients  (4.2%  vs  5.0%).  This
difference  was  maintained  at  12  months  for  both  all-cause
and  cardiovascular  deaths.
While  the  Maghreb  population  shares  some  similarities
with  the  Indian  CREATE  registry  [7],  the  rate  of  death  at  30
days  in  STEMI  patients  was  50%  lower  (4.2%  vs  8.6%),  perhaps
reﬂecting  the  very  low  rate  of  the  primary  PCI  in  the  Indian
population.  In  comparison,  the  rate  of  30-day  death  among
patients  with  NSTE-ACS  was  marginally  higher  in  ACCESS
(4.0%  vs  3.7%).  These  differences  in  outcome  may  be  due  to
variations  in  clinical  management,  but  also  to  socioeconomic
divisions  such  as  disparity  in  treatments,  type  of  hospital,
and  delays  to  presentation  and  treatment  [7].  The  low  rates
of  30-day  death  in  ACCESS  may  also  reﬂect  the  GRACE  risk
score  (mean  of  119.6  [36.9]),  which  corresponds  to  an  inter-
mediate  risk  of  death  in  patients  with  NSTE-ACS  and  a  low
risk  among  those  with  STEMI  [12].
The  12-month  rates  of  non-fatal  stroke,  non-fatal
myocardial  infarction  and  the  composite  of  cardiovascular
death,  non-fatal  stroke  and  non-fatal  myocardial  infarction
were  also  slightly  higher  in  the  Maghreb  subgroup  compared
with  the  overall  ACCESS  population  [10], whereas  the  rates
of  bleeding  were  lower,  perhaps  reﬂecting  differences  in  the
use  of  pharmacological  therapies  with  potential  bleeding
complications.
The  rate  of  death  in  the  STEMI  population  was  highest
in  Morocco  and  lowest  in  Tunisia.  These  ﬁndings  are  unex-
pected,  taking  into  account  the  greater  use  of  reperfusion
in  Morocco,  and  suggest  the  presence  of  unmeasured  factors
such  as,  for  example,  differences  in  extent  of  disease  and
delayed  thrombolysis  or  PCI.
Limitations
This  observational  study  is  subject  to  limitations  and  biases,
including  the  collection  of  non-randomized  data,  incom-
plete  information  (including  loss  to  follow-up),  potential
confounding  by  drug  indication,  dosage,  or  other  unmea-
sured  covariates,  and  potential  bias  in  site  selection.  The
patients  may  not  be  wholly  representative  of  their  countries
and  may  not  reﬂect  trends  in  other  countries  in  Africa.
Conclusions
These  observational  data,  from  three  countries  in  western
North  Africa,  provide  insights  into  the  clinical  characteris-
tics,  risk  factors,  management  and  outcomes  for  patients
hospitalized  for  an  ACS.  These  ﬁndings  demonstrate  the
need  for  strategies  aimed  at  cardiovascular  disease  pre-
vention,  as  evidenced  by  the  high  rates  of  diabetes
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ellitus,  smoking  and  alcohol  misuse.  Greater  adherence  to
vidence-based  strategies  of  cardiovascular  disease  treat-
ent,  including  more  extensive  use  of  reperfusion  therapy,
specially  primary  PCI,  alongside  reduction  in  risk  factors,
ay  in  time  lead  to  reductions  in  the  rates  of  death  due  to
ardiovascular  diseases.
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ppendix. Study deﬁnitions used in
CCESS
vent  Deﬁnition
ardiovascular  death Any  death  with  a  clear  cardiac  or  vascular  cause  (including  hemorrhagic  death  of  any
origin  and  fatal  pulmonary  embolism)  or  unknown  cause  (including  sudden  death,
unobserved  and  unexpected  death,  and  other  death  not  deﬁnitely  attributed  to  a
non-vascular  cause)
yocardial  infarction  [14] Patients  who  did  not  undergo  a  cardiac  intervention  within  the  previous  24  hours.  At
least  one  of  the  following  must  be  present:
a)  CK-MB  elevation  (>  2  ×  ULN  in  one  sample  or  >  ULN  in  two  samples);
b)  Troponin  elevation  (>  ULN  in  one  sample);
c)  Creatinine  kinase  elevation  (in  the  absence  of  a  or  b),  CK  >  2  ×ULN)
AND  at  least  one  of  the  following:
•  ischemic  symptoms  within  the  past  24  hours
•  ST  depression  of  ≥  0.1  mV  or  T-wave  inversion
•  Left  bundle  branch  block  (new  or  old)  or  paced  rhythm  that  obscures  assessment  of
ST
•  ST-elevation  (new  ST-elevation  in  ≥  2  contiguous  leads  ≥  0.2  mV  in  V1,  V2,  or  V3
or  ≥  0.1  mV  in  other  leads)
•  New  tall  R  wave  with  R/S  ≥  1  in  V1  and  R/S  ≥  1.5  in  V2
•  New  Q  waves  ≥  40  ms  in  two  contiguous  leads
Patients  who  underwent  recent  PCI  or  CABG  within  the  previous  24  hours:
a)  PCI:  CK-MB  ≥  3  ×  ULN  (no  electrocardiographic  changes  or  symptoms  required)
b)  CABG:  either  CK-MB  ≥  5  ×  ULN  and  new  Q  waves,  or  CK-MB  ≥  10  ×  ULN  (with  or
without  Q  wave)
leeding  (GUSTO  [11]) Grade  I:  severe  bleeding:  documented  intracranial  hemorrhage  or  bleeding  that
causes  hemodynamic  compromise  requiring  blood  or  ﬂuid  replacement,  inotropic
support,  ventricular  assist  devices,  surgical  intervention  (other  than  vascular  site
repair),  or  CPR  to  maintain  a  sufﬁcient  cardiac  output
Grade  II:  moderate  bleeding:  bleeding  that  requires  transfusion  of  blood  but  does  not
lead  to  hemodynamic  compromise  requiring  intervention
Grade  III:  mild  bleeding:  bleeding  not  requiring  transfusion  and  not  causing
hemodynamic  compromise,  including  subcutaneous  bleeding,  mild  hematomas,  oozing
from  puncture  sites,  etc.
schemic  stroke An  acute  brain  or  retinal  ischemic  event  with  focal  signs  either  lasting  >  24  hours  or
accompanied  by  neuroimaging  evidence  of  new  brain  infarction.  If  a  previous  deﬁcit
has  worsened,  the  worsening  must  persist  for  >  24  hours  and  should  be  accompanied
by  new  ischemic  changes  on  brain  or  CT
LN: upper limit of normal; PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft; CPR: cardiopulmonary resusci-
ation; MRI: magnetic resonance imaging; CT: computed tomography.
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